Michael A Vogelbaum is a neurosurgeon at Cleveland Clinic.[12]
He is principal investigator and co-investigator of a broad range of early phase investigator-initiated therapeutic trials, and both national and international multisite collaborative studies.[3]After completing his M.D. and Ph.D. at the University of Virginia, Vogelbaum undertook a residency in neurological surgery at Barnes-Jewish Hospital, where he also served for a year as chief resident in Neurological Surgery.[3]He has spent almost two decades at Cleveland Clinic Foundation, where he is a world-renowned expert in the diagnosis and treatment of benign and malignant tumors of the brain and spinal cord.[3]He has received support and funding from the American Cancer Society, the National Institutes of Health and the Wolf Family Foundation.[3]He has formulated and led multiple single-center and multicenter clinical trials aimed at finding new therapies for glioblastoma and other forms of brain cancer.[4]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Cleveland Clinic
2
151
40
Dr. Lathia, Dr. Michael Vogelbaum and colleagues previously reported on findings that GBM patients had higher levels of immune suppressive myeloid-derived suppressor cells in the tumor microenvironment and they tended to be resistant to and dependent on macrophage migration inhibitory factor.[6]
06/25/2020
Researchers have developed an experimental brain cancer treatment that uses a tumor-killing virus called Toca 511 to destroy cancer cells. The treatment involves injecting Toca 511 into cancer patients, where it then infects actively dividing cancer cells and gives them a gene for an enzyme called cytosine deaminase. "The collective results from this virus study, include encouraging survival and excellent safety data, support the ongoing randomized phase 2/3 trial called Toca 5, and offer hope for a new treatment option for patients with brain cancer," Vogelbaum said.[52]
06/02/2016